This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belinsky, M. G. Articles by Kruh, G. D. Search for Related Content PubMed PubMed Citation Articles by Belinsky, M. G. Articles by Kruh, G. D.

Multidrug Resistance Protein 4 Protects Bone Marrow, Thymus, Spleen, and Intestine from Nucleotide Analogue–Induced Damage

¹ Medical Science Division, ² Department of Pathology, Fox Chase Cancer Center, ³ Temple University School of Pharmacy, Philadelphia, Pennsylvania; and ⁴ National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland

Requests for reprints: Gary D. Kruh, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-5317; Fax: 215-728-3603; E-mail: gary.kruh{at}fccc.edu.

Nucleoside-based analogues are mainstays in the treatment of cancer, viral infections, and inflammatory diseases. Recent studies showing that the ATP-binding cassette transporter, multidrug resistance protein 4, is able to efflux nucleoside and nucleotide analogues from transfected cells suggests that the pump may affect the efficacy of this class of agents. However, the in vivo pharmacologic functions of the pump are largely unexplored. Here, using Mrp4^–/– mice as a model system, and the nucleotide analogue, 9'-(2'-phosphonylmethoxyethyl)-adenine (PMEA) as a probe, we investigate the ability of Mrp4 to function in vivo as an endogenous resistance factor. In the absence of alterations in plasma PMEA levels, Mrp4-null mice treated with PMEA exhibit increased lethality associated with marked toxicity in several tissues. Affected tissues include the bone marrow, spleen, thymus, and gastrointestinal tract. In addition, PMEA penetration into the brain is increased in Mrp4^–/– mice. These findings indicate that Mrp4 is an endogenous resistance factor, and that the pump may be a component of the blood-brain barrier for nucleoside-based analogues. This is the first demonstration that an ATP-binding cassette transporter can affect in vivo tissue sensitivity towards this class of agents. [Cancer Res 2007;67(1):262–8]

This article has been cited by other articles:

				R. Zhao, T. J. Raub, G. A. Sawada, S. C. Kasper, J. A. Bacon, A. S. Bridges, and G. M. Pollack Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier Drug Metab. Dispos., June 1, 2009; 37(6): 1251 - 1258. [Abstract] [Full Text] [PDF]

				A. Ose, M. Ito, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, M. Hosokawa, J. D. Schuetz, and Y. Sugiyama Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) Drug Metab. Dispos., February 1, 2009; 37(2): 315 - 321. [Abstract] [Full Text] [PDF]

				E. Hopper-Borge, X. Xu, T. Shen, Z. Shi, Z.-S. Chen, and G. D. Kruh Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B Cancer Res., January 1, 2009; 69(1): 178 - 184. [Abstract] [Full Text] [PDF]

				R. van de Ven, G. L. Scheffer, A. W. Reurs, J. J. Lindenberg, R. Oerlemans, G. Jansen, J.-P. Gillet, J. N. Glasgow, A. Pereboev, D. T. Curiel, et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration Blood, September 15, 2008; 112(6): 2353 - 2359. [Abstract] [Full Text] [PDF]

				Md. T. Hoque and S. P.C. Cole Down-regulation of Na+/H+ Exchanger Regulatory Factor 1 Increases Expression and Function of Multidrug Resistance Protein 4 Cancer Res., June 15, 2008; 68(12): 4802 - 4809. [Abstract] [Full Text] [PDF]

				N. Abla, L. W. Chinn, T. Nakamura, L. Liu, C. C. Huang, S. J. Johns, M. Kawamoto, D. Stryke, T. R. Taylor, T. E. Ferrin, et al. The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 859 - 868. [Abstract] [Full Text] [PDF]

				X. Tian, B. Swift, M. J. Zamek-Gliszczynski, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers Drug Metab. Dispos., May 1, 2008; 36(5): 911 - 915. [Abstract] [Full Text] [PDF]

				Z. P. Lin, Y.-L. Zhu, D. R. Johnson, K. P. Rice, T. Nottoli, B. C. Hains, J. McGrath, S. G. Waxman, and A. C. Sartorelli Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response Mol. Pharmacol., January 1, 2008; 73(1): 243 - 251. [Abstract] [Full Text] [PDF]